Abstract
The selective COX-2 inhibitor celecoxib has a sulfonamide structure and is contraindicated for patients with known sulfa allergy. However, there is currently no standard available for the identification of sulfonamide-related adverse drug reactions (ADRs) and the occurrence of such ADRs with celecoxib has not been established. THE AIMS OF THIS STUDY WERE: (1) to identify the typical pattern of sulfonamide ADRs from literature and verify this pattern in the World Health Organization (WHO) ADR database; and (2) to examine whether these sulfonamide ADRs occur more frequently with celecoxib than with the non-sulfonamide, COX-2 inhibitor rofecoxib. A sulfonamide ADR pattern was derived from the most extensive textbook source of ADRs and applied to the WHO database for the three groups of sulfonamide drugs: short- and intermediate-acting sulfonamides, and sulfasalazine. ADRs reported three or more times for each of these groups were included in a 'sulfonamide template' comprising 19 ADRs relating to the skin, the blood, the liver, and anaphylaxis. This template was then applied to celecoxib and rofecoxib. Overall, the relative reporting rate of a sulfonamide-type ADR with celecoxib was 80% higher than with rofecoxib, whether this was...Continue Reading
References
Aug 12, 1978·British Medical Journal·U BergmanB E Wiholm
Jan 1, 1990·Epidemiology·H A Guess, J E Thomas
Dec 26, 1986·JAMA : the Journal of the American Medical Association·M BigbyK Arndt
Jun 23, 1983·The New England Journal of Medicine·R MitsuyasuP Volberding
Dec 1, 1996·Seminars in Cutaneous Medicine and Surgery·M Mockenhaupt, E Schöpf
Jan 25, 2000·Clinical Therapeutics·R PattersonJ Lefkowith
Sep 9, 2000·JAMA : the Journal of the American Medical Association·F E SilversteinG S Geis
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Jul 18, 2001·PharmacoEconomics·R M Herings, O H Klungel
Sep 26, 2001·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·M Sánchez BorgesC R Pérez
Citations
Jul 26, 2002·Pharmacoepidemiology and Drug Safety
Mar 17, 2007·Journal of Clinical Immunology·Kamlesh Bhatt, Padmini Salgame
Sep 3, 2005·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Mario Sánchez-BorgesArnaldo Capriles-Hulett
Nov 4, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Joaquin QuiralteJosé Conde
Nov 16, 2004·American Journal of Therapeutics·Mario Sánchez-BorgesFernan Caballero-Fonseca
Oct 21, 2003·The Annals of Pharmacotherapy·Vicente Palop-LarreaInocencia Martínez-Mir
Jun 1, 2006·The Annals of Pharmacotherapy·B Marianne VerdelHubert Gm Leufkens
Mar 21, 2009·The Annals of Pharmacotherapy·Kevin W Chamberlin, Adam R Silverman
Jul 28, 2004·European Journal of Clinical Pharmacology·Deborah LaytonSaad A W Shakir
Jul 29, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·I Ralph Edwards
May 8, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bengt-Erik Wiholm
Feb 13, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Lori E ShapiroNeil H Shear
Mar 13, 2019·Fundamental & Clinical Pharmacology·Mohammad BakhriansyahOlaf H Klungel
May 21, 2003·British Journal of Clinical Pharmacology·Munir Pirmohamed, B Kevin Park
Apr 3, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·I Ralph Edwards